Purpose: Visfatin, protein secreted by visceral adipose tissue, visfatin is an intracellular enzyme that has insulin-mimetic effects and lowers plasma glucose levels. Data about the role of visfatin in newly diagnosed glucose metabolism abnormalities are limited. The aim of the work was to assess serum concentration of visfatin in impaired fasting glucose and impaired glucose tolerance. Materials and Methods: 57 patients with diagnosis of abnormal glucose metabolism were divided into the subgroups according to the oral glucose tolerance test (OGTT) results as impaired fasting glucose(IFG) (n=39) and IFG+ impaired glucose tolerance (IGT) (n=18). The control group consisted of 44 healthy controls with normal glucose tolerance and without any metabolic disorders. Serum lipids, high sensitive CRP, uric acide, glycated haemoglobin (HbA1c) and serum visfatin levels were measured in all participants. Results: The mean visfatin level of IFG group was 93.92±12.95, IFG+IGT group was 37.79±29.36 and control group was 43.96±38.57. There was statistically significant difference between serum visfatin levels of the groups (p<0.001). Mean visfatin level of IFG group was statistically higher than IFG+IGT and control groups (respectively p<0.001, p<0.001). Mean visfatin level of IFG+IGT group was lower than the control group however, the difference was not statistically significant (p=0.785). Visfatin levels were negatively correlated with total cholesterol, HDL, LDL, hsCRP, ferritin and HbA1c levels, positively correlated with TG, HOMA-ir and BMI values, however these relationships were not statistically significant. Conclusion: Visfatin levels of patients with IFG were higher than healthy controls however, visfatin levels were not correlated with HOMA-ir, BMI, TG, HDL, LDL, hsCRP, ferritin, MPV, HbA1c and cholesterol levels.